Tecartus (brexucabtagene autoleucel)

pCPA File Number: 22340

Negotiation Status:

Active Negotiation

Indication(s):

For treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)

Sponsor/Manufacturer:

Gilead Sciences Canada Inc.

CADTH Project Number:

PG0304

pCPA Engagement Letter Issued:

2023-05-19

Negotiation Process Concluded:

Not Applicable